Lorem Vascular Pty Ltd.

近日，加拿大生物制药公司SaNOtize宣布完成2400万美元的B轮融资。本轮融资由Horizons Ventures和OurCrowd共同领投，农银国际（ABC International）跟投。这笔资金将用于正在进行的一氧化氮鼻喷雾剂(NONS™)预防新冠病毒的3期试验和其他研究。虽然药物和疫苗已经减弱了新冠肺炎的影响，但SaNOtize认为我们仍然需要更好的方式来预防和治疗新型冠状病毒。首席执行官Gilly Regev博士说：“我们的临床研究发现，即使在德尔塔和奥密克戎激增的情况下，NONS™用于预防和治疗新冠肺炎也是安全有效的。”这家总部位于温哥华的公司致力于应用一氧化氮（NO）的抗菌特性。通过使用其独家NO释放溶液（NORS™），SaNOtize尝试将NO应用于喷雾剂、沐浴剂、灌洗剂、凝胶和乳霜制造中。使冠状病毒载量48小时内降低99%以上，感染风险降低75%SaNOtize的专有液体配方NORS™是一种一氧化氮（NO）输送平台，不仅可用于释放NO气体，也可制备带有NO的凝胶或乳膏。作为一种对细菌、病毒和真菌有效的非抗生素抗微生物剂，NORS™可以通过其递送机制清除广谱的传染性病原体，并减少使用抗生素的频率。SaNOtize希望该技术能够减缓抗菌素耐药性(AMR)的发展，减少呼吸道感染的传播。NO是人体多种细胞产生的纳米分子，参与人体许多重要的生理过程，例如心血管健康和免疫反应。二十多年来，医学界一直在探索气态NO的应用边界。其中通过大型气瓶和呼吸机输送来治疗早产儿呼吸衰竭的疗法较为常见。与此同时，NO也被证明是一种高效的抗菌剂，可以杀死病毒、细菌和真菌，包括导致新冠肺炎的病毒SARS-CoV-2。然而，在处理许多传染病时，尤其是那些局部的传染病，通过气瓶输送气态NO是不切实际的。SaNOtize基于NORS™这一专利，研发出不受限于使用场景的鼻腔喷雾产品NONS™，产品组合包括VirX™和enovid™，分别面向海内外新冠肺炎治疗市场。当喷雾从瓶尖释放时便会产生剂量可控的NO，阻断病毒感染细胞所需的ACE-2受体，破坏冠状病毒突变体。NONS™治疗新冠肺炎的3期临床研究发现，它可以使SARS-CoV-2病毒载量在24小时内降低94%以上，在48小时内降低99%以上。2022年4月，SaNOtize开展了NONS™预防新冠肺炎的回顾性临床试验。他们发现，使用NONS™的参与者感染率为6.4%，而对照组为25.6%（P<0.0001），证明该药物可以将感染风险降低75%。目前，SaNOtize计划在加拿大和斯里兰卡招募4000名志愿者参加3期临床试验，以评估NONS™作为预防新冠肺炎感染的抗病毒药物的安全性和有效性。VirX™和enovid™ 图源：SaNOtize官网冠状病毒通过空气中的飞沫传播到鼻粘膜，在三天的潜伏期内繁殖，破坏鼻粘膜细胞，然后通过鼻分泌物携带到下呼吸道，导致病毒性肺炎。疫苗接种是主要的预防手段，但让大部分公众完成接种也需要时间。另外，病毒可能会出现突变株，并且目前尚不清楚免疫保护将持续多长时间。出于这些原因，尽快找到并提供简单、安全和普惠的非处方解决方案非常重要。北美和欧洲的一些制药公司正在进行利用NO治疗重症新冠肺炎患者的临床试验。其中SaNOtize的解决方案易于使用，且费用较低，两支装的enovid™售价为125美元。“这种简单的治疗方法将帮助我们恢复正常的生活。即使吸入了病毒，我们也可以通过定期使用SaNOtize来预防和消灭它。”前英国政府部长Rob Wilson说。  五年完成千万美元融资，旗舰产品在亚洲多国上市SaNOtize由Gilly Regev和Chris Miller于2017年创立。首席执行官兼联合创始人Gilly Regev在耶路撒冷希伯来大学获得生物化学博士学位。她在生物化学、分析化学、微生物学领域拥有30年的研发经验，过去12年从事一氧化氮方面的工作，包括担任Bovicor（动物保健公司）首席科学官。另外，她还是一名经验丰富的生物技术高管，熟悉药物开发、知识产权开发、早期生物技术筹款、许可交易和临床试验方面的工作。首席科学官兼联合创始人Chris Miller博士拥有在一氧化氮生物技术初创公司筹款和许可方面的经验，以及20年临床试验设计、知识产权、监管和管理经验。此外，他还担任加拿大不列颠哥伦比亚大学医学院、呼吸与传染病学系退休助理教授。Chris Miller（左）和Gilly Regev（右） 图源：The Jewish Chronicle2020年，SaNOtize从国家研究委员会获得了40万美元的资助。随后，SaNOtize向联邦战略创新基金提出了一系列申请。在2020年联邦预算中，该基金获得了7.52亿加元的拨款，用于帮助加拿大公司开展针对新冠肺炎的医疗对策，提升其临床试验和制造能力。2021年8月，Glenmark与SaNOtize建立了独家长期合作伙伴关系，在印度和包括新加坡、马来西亚在内的其他几个亚洲国家和地区生产、营销和分销NONS™。2022年1月，SaNOtize与Cytori签署了NONS™在日本的独家经销协议。根据该协议，Cytori计划开始与药品和医疗器械局（PMDA）就药品战略进行咨询，旨在尽早获得批准。2022年2月，该喷雾剂获得印度药物监管机构的批准，以及Glenmark Pharmaceuticals的生产许可。目前NONS™已经在以色列、巴林、印尼在内的一些国家上市，被认证为医疗器械。它还在新加坡、尼泊尔和欧盟注册为I类医疗器械，并获得CE标志（欧洲合格认证）。2022年8月24日，SaNOtize宣布完成2400万美元的B轮融资，以推进其基于NO的产品研发。本轮融资由Horizons Ventures和OurCrowd共同领投，农银国际跟投。OurCrowd首席执行官Jon说：“我们很高兴参与这一轮融资，随着临床结果的增加和他们在更多国家获得监管部门的批准，其产品将在全球受到越来越多的关注。”SaNOtize融资历史 图源：动脉网近日，SaNOtize入围2022年Fierce创新奖。该奖项由Fierce Biotech和Fierce Pharma共同主办。专家评审小组将根据企业提交的材料，评选出最有可能对医药行业产生影响力的创新的公司。SaNotize研发管线 图源：SaNOtize官网除了用于治疗和预防新冠肺炎，SaNOtize还在探索NO治疗其他适应症的方法。目前，该公司治疗慢性鼻窦炎的I/II期疗效研究已完成注册；其足浴疗法作为糖尿病足溃疡治疗方法的I/II期疗效研究正在招募患者并由美国国防部资助。此外，SaNOtize于2018年获得了一项工业研究援助计划(IRAP)的资助，以开发一种治疗甲真菌病的药物组合。左右滑动查看更多近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台

SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) today provided a business and financial performance update in its presentation at the Cowen and Company 35th Annual Health Care Conference in Boston today. The corporate presentation includes certain top-line preliminary unaudited financial results for the quarter and full year ended December 31, 2014 and select performance guidance for the full-year 2015. Help employers find you! Check out all the jobs and post your resume.

Cytori Therapeutics, Inc. to Raise $13.5 Million in Registered Direct Offering SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (CYTX) entered into a definitive securities purchase agreements to raise an aggregate of $13.5 million in a registered direct offering, with net proceeds estimated to be approximately $12.5 million, after deducting placement agent fees and estimated offering expenses. At closing, Cytori will issue and sell to select investors 13,500 units, with each unit consisting of one share of its Series A 3.6% convertible preferred stock, which shall be convertible into the Company’s common stock (the “Conversion Shares”) and warrants to purchase up to a number of shares of common stock equal to 100% of the Conversion Shares. Cytori plans to use the net proceeds from this offering for working capital and general corporate purposes, which include funding its ongoing and future clinical studies. The convertible preferred stock is convertible into shares of Cytori’s common stock at the option of the investors at a conversion price of $0.52, subject to certain adjustments and limitations on conversion until such time as Cytori stockholders approve the transaction and an increase in the number of authorized shares of its common stock. The convertible preferred stock will accrue a 3.6% cumulative dividend until stockholder approval is obtained. The investors also will receive warrants to purchase an aggregate of 25,961,540 shares of Cytori’s common stock. The warrants will have an exercise price of $0.5771 per share, will be exercisable six months after the date of issuance and will expire five years from the initial exercise date. The convertible preferred stock and the warrants are immediately separable and will be issued separately. The closing of the offering is expected to take place on or about October 13, 2014, subject to the satisfaction of customary closing conditions. Roth Capital Partners acted as the lead placement agent for the offering and Maxim Group LLC served as a co- placement agent for the offering. The convertible preferred stock and warrants, and the common stock issuable upon conversion of the convertible preferred stock and exercise of the warrants, are being offered by Cytori pursuant to an effective registration statement(s) on Form S-3 previously filed with the Securities and Exchange Commission (“SEC”). The Company filed a prospectus supplement relating to the offering with the SEC on October 8, 2014, which is available along with the accompanying base prospectus filed with the SEC in connection with the shelf registration, on the SEC’s website at or by sending a request to: Roth Capital Partners, 888 San Clemente, Suite 400, Newport Beach, CA 92660, (800) 678-9147. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Cytori, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended. About Cytori Therapeutics, Inc. Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® system product family. For more information visit Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. Such statements, including, but not limited to, those regarding the Company’s expectations regarding its fundraising efforts, including the closing of the public offering, the anticipated use of proceeds from the offering, the immediate and substantial dilution in book value per share of the common stock, and the limited rights and lack of a public market with respect to the warrants being issued, involve known and unknown risks that relate to the Company’s future events or future financial performance and the actual results could differ materially from those discussed in this communication. These and other factors are identified and described in more detail in our filings with the SEC, including the prospectus supplement filed with the SEC on October 8, 2014 and the Company’s Form 10-K, Forms 10-Q and its other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events. Contact: Cytori Therapeutics, Inc. Tiago Girao, 1-858-458-0900 Chief Financial Officer ir@cytori.com Help employers find you! Check out all the jobs and post your resume.